[ 1 ] de Gramont A, Figer A, Seymour M, et al. Leucovorin and uorouracil with or without oxaliplatin as rst-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
[2]
[ 2 ] Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated uorouracil-leucovorin as rst-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2000, 18(1): 136-147.
[3]
[ 3 ] Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with uorouracil compared with uorouracil alone as rst-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. Lancet, 2000, 355(9209): 1041-1047.
[4]
[ 4 ] Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer[J]. N Engl J Med, 2005, 352: 476-487.
[5]
[ 5 ] Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with uorouracil/folinic acid plus oxaliplatin as rst-line therapy for metastatic colorectal cancer[J]. J Clin Oncol， 2008，26(12): 2006-2012.
[6]
[ 6 ] Diaz-Rubio E, Tabernero J, Gomez-Espana A， et al. Phase Ⅲ study of capecitabine plus oxaliplatin compared with continuous-infusion uorouracil plus oxaliplatin as rst-line therapy in metastatic colorectal cancer: nal report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial[J]. J Clin Oncol, 2007, 25(27): 4224-4230.
[ 7 ] Ohtsu A, Baba H, Sakata Y, et al. PhaseⅡ study of S-1, a novel oral uoropyrimidine derivative, in patients with metastatic colorectal carcinoma.[J]. Br J Cancer， 2000，83(2): 141-145.
[9]
[ 8 ] Shirao K, Ohtsu A, Takada H, et al. PhaseⅡ study of oral S-1 for treatment of metastatic colorectal carcinoma[J]. Cancer, 2004, 100(11): 2355-2361.
[10]
[ 9 ] Malik ST, Talbot D, Clarke PI, et al. PhaseⅡ trial of UFT in advanced colorectal and gastric cancer[J]. Br J Cancer, 1990, 62(6): 1023-1025.
[11]
Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum[J]. Biomed Pharmacother, 1989, 43(4): 237-250.
Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity[J]. Br J Cancer, 2002, 86(7): 1162-1168.
[15]
Boisdron-Celle M，Craipeau C，Brienza S，et al，Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences[J]. Cancer Chemother Pharmacol，2002，49(3): 235-243.
[16]
Li J, Yin J, Zhu X, et al. PhaseⅠ dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer[J]. Anticancer Drugs, 2008, 19(7): 745-748.
[17]
Kim HS, Park MJ, Uhm JE, et al. A phaseⅠ trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer[J]. Int J Colorectal Dis, 2009, 24(11): 1311-1316.
[18]
Hong YS, Lee JL, Park JH, et al. PhaseⅠ study of preoperative chemoradiation with S-1 and oxaliplatin in patients with locally advanced resectable rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79(3): 684-689.
[19]
Zang DY, Lee BH, Park HC, et al. PhaseⅡ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J]. Ann Oncol, 2009, 20(5): 892-896.
[20]
Doi Y, Okada T, Matsumoto H, et al. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model[J]. Cancer Sci, 2010, 101(11): 2470-2475.
[21]
Hong J, Han SW, Ham HS, et al. PhaseⅡ study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis[J]. Cancer Chemother Pharmacol, 2011, 67(6): 1323-1331.
